ALX ONCOLOGY
ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer. It is an independent, private biotechnology company. The founding of Alexo Therapeutics was based upon technology invented by Aaron Ring, K. Christopher Garcia, Kipp Weiskopf, Aron Levin, and Irving Weissman at Stanford University. This discovery involves soluble versions of signal regulatory protein-α (SIRPα) that have been engineered to bind CD47 with significantly greater affinity than natural SIRPα.1.
ALX ONCOLOGY
Industry:
Biopharma Biotechnology Health Care Life Science Therapeutics
Founded:
2015-01-01
Address:
San Francisco, California, United States
Country:
United States
Website Url:
http://www.alxoncology.com
Total Employee:
11+
Status:
Active
Contact:
(353) 161-8000
Total Funding:
166 M USD
Technology used in webpage:
Google Apps For Business Google Maps Google GStatic Google Static Content Google Maps API Google Cloud Google Cloud Oregon Dyn DNS
Current Advisors List
Board_observer
Advisor
2020-09-01
Current Employees Featured
Jaume Pons President, Chief Executive Officer and Co-Founder @ ALX Oncology
President, Chief Executive Officer and Co-Founder
Hong I. Wan Chief Scientific Officer @ ALX Oncology
Chief Scientific Officer
2017-06-01
John Borgeson Chief Financial Officer @ ALX Oncology
Chief Financial Officer
Sophia Randolph Chief Medical Officer @ ALX Oncology
Chief Medical Officer
2016-01-01
Michael Chang Vice President, Operations @ ALX Oncology
Vice President, Operations
2015-01-01
Janet Sim Vice President, Protein Science @ ALX Oncology
Vice President, Protein Science
2018-07-01
Hank Stern Vice President, Chemistry, Manufacturing, and Controls @ ALX Oncology
Vice President, Chemistry, Manufacturing, and Controls
2015-01-01
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2021-10-07 | ScalmiBio | ScalmiBio acquired by ALX Oncology | 4.5 M USD |
Investors List
Cormorant Asset Management
Cormorant Asset Management investment in Series C - ALX Oncology
venBio Partners
venBio Partners investment in Series C - ALX Oncology
Logos Capital
Logos Capital investment in Series C - ALX Oncology
Vivo Capital
Vivo Capital investment in Series C - ALX Oncology
Lightstone Ventures
Lightstone Ventures investment in Series C - ALX Oncology
Foresite Capital
Foresite Capital investment in Series C - ALX Oncology
BVF Partners
BVF Partners investment in Series C - ALX Oncology
Janus Henderson Investors
Janus Henderson Investors investment in Series C - ALX Oncology
HBM Healthcare Investments AG
HBM Healthcare Investments AG investment in Series C - ALX Oncology
Lightstone Ventures
Lightstone Ventures investment in Convertible Note - ALX Oncology
Official Site Inspections
http://www.alxoncology.com Semrush global rank: 1.12 M Semrush visits lastest month: 28.58 K
- Host name: 215.12.198.104.bc.googleusercontent.com
- IP address: 104.198.12.215
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "ALX Oncology"
About Us - ALX Oncology
Innovative Science. We are advancing a validated, differentiated scientific approach supported by ongoing, cutting-edge research that has demonstrated the ability to overcome challenges and the potential to meaningfully change the …See details»
Board of Directors • ALX Oncology
Prior to Relypsa, Mr. Garland spent three years as Chief Commercial Officer at Exelixis, where he built the commercial organization for the company’s launch of cabozantinib in medullary …See details»
Release Details - ir.alxoncology.com
Mar 5, 2025 To ensure that the company is strongly positioned to focus on our highest priority programs, we are streamlining our organization and prioritizing resources to execute on our …See details»
ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors
Aug 6, 2024 - Dr. Sandler brings more than 30 years of experience and leadership in oncology and drug development - - Jaume Pons, Ph.D., and Sophia Randolph, M.D., Ph.D., will leave …See details»
ALX Oncology - Crunchbase Company Profile & Funding
ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer. It is an independent, private biotechnology company.See details»
ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial ...
Mar 6, 2025 Yesterday during our R&D Day webcast, we shared updates on how we are prioritizing operations and capital to support our new and ongoing clinical programs that are …See details»
ALX Oncology Holdings Inc. (ALXO) - Yahoo Finance Canada
See the company profile for ALX Oncology Holdings Inc. (ALXO) including business summary, industry/sector information, number of employees, business summary, corporate governance, …See details»
ALX Oncology - LinkedIn
ALX Oncology Biotechnology Research South San Francisco, California 5,598 followers ALX Oncology is a clinical-stage biotechnology company advancing cancer therapies by boosting the immune system.See details»
Scientific Advisory Board • ALX Oncology
Dr. Baum is Chief Executive Officer at Terremoto and has served on the board of directors since July 2023. Prior to becoming the CEO at Terremoto, Dr. Baum was the Founder, President …See details»
ALX Oncology - Craft
ALX Oncology has 5 employees across 2 locations and $1.18 m in annual revenue in FY 2020. See insights on ALX Oncology including office locations, competitors, revenue, financials, …See details»
ALX Oncology - Overview, News & Similar companies - ZoomInfo
Oct 3, 2024 View ALX Oncology (alxoncology.com) location in California, United States , revenue, industry and description. Find related and similar companies as well as employees …See details»
Release Details - ALX Oncology
Oct 5, 2022 Investor Contact: Peter Garcia Chief Financial Officer, ALX Oncology (650) 466-7125 Ext. 113 peter@alxoncology.com Argot Partners (212)-600-1902 …See details»
ALX Oncology Holdings Inc. (ALXO) - Yahoo Finance
See the company profile for ALX Oncology Holdings Inc. (ALXO) including business summary, industry/sector information, number of employees, business summary, corporate governance, …See details»
ALX Oncology 2025 Company Profile: Stock Performance
ALX Oncology General Information Description. ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline …See details»
ALX Oncology Information - RocketReach
Alxoncology.com; 2 415225XXXX; 603668XXXX; Michael Chang Vice President Operations at ALX Oncology California, United States View. 2 hotmail.com; alxoncology.com; 1 …See details»
ALX Oncology - Company Profile - Tracxn
Jan 28, 2025 Email ID: *****@alxoncology.com; Key Metrics. Total Funding. $123M in 2 rounds. Latest Funding Round. Series C, Feb 12, 2020, $105M. Investors. Vivo Capital & 10 more. …See details»
ALX lays off 30% of staff to pay for more trials of CD47 blocker
Mar 5, 2025 ALX Oncology is laying off 30% of its workforce as the biotech seeks to channel its cash into further trials of its CD47 blocker.. The drug, called evorpacept, is in a pair of phase 2 …See details»
Release Details - ir.alxoncology.com
Jan 22, 2025 ir@alxoncology.com. Media Contact: Audra Friis, Sam Brown, Inc. audrafriis@sambrown.com (917) 519-9577. Shareholder Tools. Print Page Email Alerts RSS …See details»
Events and Presentations • ALX Oncology
The Investor Relations website contains information about ALX Oncology's business for stockholders, potential investors, and financial analysts.See details»
ALX Oncology | HBM Healthcare
Www.alxoncology.com. Company status: Public. ALX Oncology is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block …See details»